About Biocon Our Business Research & Development Biocon's Technology Investors Media Careers CSR
  > INVESTORS
  Overview
  Corporate Structure
  Corporate Governance
  Company History
  Annual General Meeting
  Postal Ballot
  Investor FAQs
  Stock Info
  Financial Results
  Subsidiary Financials
  Annual Report
  Disclosure to Stock Exchange
  Nomination form
  Press Releases
  Presentations
  Analyst Coverage
  Investor Contacts
  
  
     
 
Disclosure to Stock Exchange

  December 2018
20 Dec Meetings conducted with Institutional Investors/Research Analysts Download Pdf
19 Dec Meetings conducted with Institutional Investors/Research Analysts Download Pdf
10 Dec Meetings conducted with Institutional Investors/Research Analysts Download Pdf
03 Dec Change in name of Registrar & Share Transfer Agent- Karvy Computershare Private Limited to Karvy Fintech Private Limited Download Pdf
  November 2018
30 Nov Biosimilar Pegfilgrastim Co-Developed by Biocon Receives Approval in EU Download Pdf
27 Nov Meetings conducted with Institutional Investors/Research Analysts. Download Pdf
26 Nov Change in the name & contact details of Key Managerial Personnel under the Policy for Determination of Materiality of disclosures Download Pdf
23 Nov Meetings conducted with Institutional Investors/Research Analysts. Download Pdf
21 Nov Meetings conducted with Institutional Investors/Research Analysts. Download Pdf
16 Nov Investor Presentation for Quarter ended September 30, 2018 Download Pdf
16 Nov Meetings conducted on November 16, 2018 with Institutional Investors/Research Analysts. Download Pdf
15 Nov Meetings conducted with Institutional Investors/Research Analysts. Download Pdf
12 Nov Meetings conducted on November 12, 2018 with Institutional Investors/Research Analysts. Download Pdf
12 Nov Biocon's Generic Formulations Facility in Bengaluru completes U.S. FDA Inspection with No 483 observations Download Pdf
9 Nov Meetings conducted on November 8, 2018 and November 9, 2018 with Institutional Investors/Research Analysts. Download Pdf
  October 2018
25 Oct Biocon Q2FY19 Earnings PressRelease Download Pdf
19 Oct Biocon and Mylan Announce Positive CHMP Opinion for Ogivri®, Biosimilar Trastuzumab Download Pdf
08 Oct Intimation of Board Meeting scheduled on Thursday, October 25, 2018. Download Pdf
  September 2018
27 Sep Meetings conducted on September 26, 2018 and September 27, 2018, with Institutional Investors/Research Analysts. Download Pdf
22 Sep Biocon’s Drug Substance Facility in Bangalore completes US FDA inspection with no observations Download Pdf
21 Sep Biocon and Mylan Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim - Press Release Download Pdf
20 Sep Meetings conducted on September 19, 2018 and September 20, 2018, with Institutional Investors/Research Analysts Download Pdf
11 Sep Disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011 and Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015. Download Pdf
11 Sep Meetings conducted on September 10, 2018, with Institutional Investors/Research Analysts Download Pdf
10 Sep Meetings conducted on September 07, 2018, with Institutional Investors/Research Analysts Download Pdf
07 Sep Meetings conducted on September 06, 2018, with Institutional Investors/Research Analysts. Download Pdf
06 Sep Meetings conducted on September 05, 2018, with Institutional Investors/Research Analysts Download Pdf
05 Sep Meetings conducted on September 04, 2018, with Institutional Investors/Research Analysts Download Pdf
03 Sep Appointment of Key Managerial Personnel Download Pdf
03 Sep Investor Presentation Announcement for Quarter ended June 30, 2018 Download Pdf
  August 2018
28 Aug Meeting and teleconference conducted on August 27, 2018 and on August 28, 2018 respectively, with Institutional Investors/Research Analysts Download Pdf
23 Aug Meeting and teleconference conducted on August 23, 2018 with Institutional Investors/Research Analysts Download Pdf
16 Aug Meeting conducted on August 15, 2018 with Institutional Investors/Research Analysts Download Pdf
14 Aug Meeting conducted on August 13, 2018 with Institutional Investors/Research Analysts Download Pdf
09 Aug Meeting conducted on August 08, 2018 with Institutional Investors/Research Analysts Download Pdf
06 Aug Meeting conducted on August 06, 2018 with Investors/Research Analysts Download Pdf
03 Aug Teleconference conducted on August 03, 2018 with Investors/Research Analysts Download Pdf
01 Aug Teleconference conducted on July 31, 2018 with Investors/Research Analysts Download Pdf
  July 2018
28 July Announcement on appointment of Mr. Bobby Kanubhai Parikh as Independent Director Download Pdf
28 July Proceedings of Annual General Meeting including Voting Results and Scrutinizer’s Report Download Pdf
26 July Audited Financial Results (Standalone and consolidated) for Q1FY19 Download Pdf
26 July Outcome of the Board Meeting held on 26 July 2018 Download Pdf
26 July Biocon Q1FY19 Earnings PressRelease Download Pdf
05 July Intimation of Board Meeting for approving unaudited Q1 financials Download Pdf
04 July Company Statement: Biocon's Sterile Drug Product facility receives EU GMP Certification Download Pdf
  June 2018
27 June Intimation regarding Meeting with Investor Download Pdf
23 June Biocon’s Sterile Drug Product facility Receives EIR from USFDA Download Pdf
22 June Intimation regarding Teleconference with Investor Download Pdf
05 June Meeting conducted on 4th & 5th of June 2018 with Institutional Investors/Research Analysts. Download Pdf
05 June U.S. FDA approves Mylan and Biocon's FulphilaTM (pegfilgrastim-jmdb), the first Biosimilar to Neulasta Download Pdf
04 June Tata Memorial Hospital team presents Biocon’s Nimotuzumab study results at American Society of Clinical Oncology (ASCO) Annual Meeting 2018 Download Pdf
02 June Biocon and Mylan Press Release pertaining to presenting new data to American society of Clinical Oncology (ASCO) Download Pdf
  May 2018
18 May SAST Regulation 29(2) Download Pdf
18 May Intimation regarding Sale of Equity Shares of the Syngene International Limited Download Pdf
15 May Intimation regarding Analysts/ Institutional Investors meet Download Pdf
09 May Intimation regarding Analysts/ Institutional Investors meet Download Pdf
08 May Intimation regarding Analysts/ Institutional Investors meet Download Pdf
02 May Meeting / teleconference conducted on 1st and 2nd of May 2018 with In stitutional Investors / Research Analysts. Download Pdf
02 May Company Statement on Biocon Regulatory Audit Update Download Pdf
  April 2018
26 April

Audited Financial Results (Standalone and consolidated) for the quarter and year ended 2017-18

Download Pdf
26 April

Outcome of the board meeting held on 26th April, 2018

Download Pdf
26 April

Press Release for the quater and financial year ended 2017-18

Download Pdf
16 April

Proposal to consider recommendation of final dividend

Download Pdf
11 April

Company Statement: Mylan and Biocon seek to accelerate introduction of Adalimumab biosimilar in EU

Download Pdf
05 April

Intimation of Board Meeting Ref: Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Download Pdf
  March 2018
28 Mar

Mylan and Biocon Receive Approvals from the European Commission and TGA Australia for Semglee™, Biosimilar Insulin Glargine

Download Pdf
27 Mar

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
20 Mar

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
16 Mar

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
15 Mar

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
14 Mar

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
13 Mar

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
02 Mar

Intimation regarding change in Compliance Officer under Regulation 30 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.

Download Pdf
02 Mar

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
  February 2018
27 Feb

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
22 Feb

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
21 Feb

Company Statement on US-FDA Inspection at Biocon Malaysia

Download Pdf
20 Feb

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
15 Feb

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
08 Feb

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
08 Feb

Intimation regarding Analysts/ Institutional Investors meet

Download Pdf
06 Feb

Intimation regarding Analysts/Institutional Investors Meet

Download Pdf
05 Feb

Analysts/Institutional Investors Presentation

Download Pdf
02 Feb

Intimation regarding Analysts/Institutional Investors Meet

Download Pdf
  January 2018
30 Jan

Intimation regarding Analysts/Institutional Investors Meet

Download Pdf
29 Jan

Intimation regarding Analysts/Institutional Investors Meet

Download Pdf
29 Jan

Press Release Media Release

Download Pdf
29 Jan

Biocon Insider Trading Code 2015 - Amended on Jan 24, 2018

Download Pdf
24 Jan

Biocon Document Retention and Archival Policy - Amended on Jan 24, 2018

Download Pdf
24 Jan

Outcome of Board Meeting

Download Pdf
23 Jan

Intimation under Regulation 30 of SEBI Regulations, 2015

Download Pdf
18 Jan

Biocon Announces Exclusive Global Collaboration with Sandoz on Next-Generation Biosimilars

Download Pdf

 
     
 January to June 2020
 January to December 2019
 January to December 2018
 January to December 2017
 January to December 2016
 December 2015
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved